Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients

Judith Heggen, Carla West, Ellen Olson, Thomas Olson, Gerald Teague, James Fortenberry, Andrew M Yeager

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective. Diffuse alveolar hemorrhage (DAH) is defined as a syndrome of hypoxia, dyspnea, infiltrates on chest radiograph, and bloody fluid on successive bronchoalveolar lavages without apparent infection. Minimal experience has been reported with DAH after hematopoietic cell transplant (HCT) in children. We reviewed the incidence, management and outcome of DAH in a pediatric HCT population. Methods. Retrospective review of 138 patients undergoing allogeneic (n = 89) or autologous (n = 49) HCT at a referral children's medical center between January 1996 and April 2000. Results. Seven (5.1%) of 138 patients met criteria for DAH; all were allogeneic recipients. Mean age of DAH patients was 11 years (range: 1.4-15.2). Median onset of DAH following HCT was day 24 (range: 10-50), median day of engraftment day 20 and white blood cell count 0.54 × 109/L (range: <0.1-7.03), with no difference between survivors and nonsurvivors. All patients developed clinical respiratory failure and 6 required intubation, with PaO2/fraction of inspired oxygen <200. Patients were intubated a median of 12 days (range: 1-75). All patients experienced >1 episode of bleeding and 3 patients required reintubation after successful extubation resulting from recurrent DAH. Bronchoalveolar lavage fluid cultures were negative for viruses, bacteria and fungi. All DAH patients received steroids. Three patients died with progressive pulmonary failure and other organ system involvement. Four of 7 DAH patients (57%) survived to discharge, but 3 died from disease relapse at days 116, 138, and 273 post-HCT. Conclusion. DAH occurred more frequently in allogeneic HCT recipients compared with autologous recipients. Onset of DAH coincided closely with white blood cell engraftment. Although associated with significant respiratory failure and need for mechanical ventilation, HCT patients can survive DAH.

Original languageEnglish (US)
Pages (from-to)965-971
Number of pages7
JournalPediatrics
Volume109
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Pediatrics
Hemorrhage
Transplants
Bronchoalveolar Lavage Fluid
Bronchoalveolar Lavage
Leukocyte Count
Artificial Respiration
Respiratory Insufficiency
Dyspnea
Leukocytes
Fungi
Thorax
Referral and Consultation
Steroids
Viruses
Bacteria
Recurrence
Lung
Incidence
Infection

Keywords

  • Bone marrow transplant
  • Bronchoalveolar lavage
  • Pediatric
  • Pulmonary hemorrhage
  • Respiratory failure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Heggen, J., West, C., Olson, E., Olson, T., Teague, G., Fortenberry, J., & Yeager, A. M. (2002). Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. Pediatrics, 109(5), 965-971. https://doi.org/10.1542/peds.109.5.965

Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. / Heggen, Judith; West, Carla; Olson, Ellen; Olson, Thomas; Teague, Gerald; Fortenberry, James; Yeager, Andrew M.

In: Pediatrics, Vol. 109, No. 5, 2002, p. 965-971.

Research output: Contribution to journalArticle

Heggen, J, West, C, Olson, E, Olson, T, Teague, G, Fortenberry, J & Yeager, AM 2002, 'Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients', Pediatrics, vol. 109, no. 5, pp. 965-971. https://doi.org/10.1542/peds.109.5.965
Heggen J, West C, Olson E, Olson T, Teague G, Fortenberry J et al. Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. Pediatrics. 2002;109(5):965-971. https://doi.org/10.1542/peds.109.5.965
Heggen, Judith ; West, Carla ; Olson, Ellen ; Olson, Thomas ; Teague, Gerald ; Fortenberry, James ; Yeager, Andrew M. / Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients. In: Pediatrics. 2002 ; Vol. 109, No. 5. pp. 965-971.
@article{2db1fa2e8d634eeb973546b5709231cf,
title = "Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients",
abstract = "Objective. Diffuse alveolar hemorrhage (DAH) is defined as a syndrome of hypoxia, dyspnea, infiltrates on chest radiograph, and bloody fluid on successive bronchoalveolar lavages without apparent infection. Minimal experience has been reported with DAH after hematopoietic cell transplant (HCT) in children. We reviewed the incidence, management and outcome of DAH in a pediatric HCT population. Methods. Retrospective review of 138 patients undergoing allogeneic (n = 89) or autologous (n = 49) HCT at a referral children's medical center between January 1996 and April 2000. Results. Seven (5.1{\%}) of 138 patients met criteria for DAH; all were allogeneic recipients. Mean age of DAH patients was 11 years (range: 1.4-15.2). Median onset of DAH following HCT was day 24 (range: 10-50), median day of engraftment day 20 and white blood cell count 0.54 × 109/L (range: <0.1-7.03), with no difference between survivors and nonsurvivors. All patients developed clinical respiratory failure and 6 required intubation, with PaO2/fraction of inspired oxygen <200. Patients were intubated a median of 12 days (range: 1-75). All patients experienced >1 episode of bleeding and 3 patients required reintubation after successful extubation resulting from recurrent DAH. Bronchoalveolar lavage fluid cultures were negative for viruses, bacteria and fungi. All DAH patients received steroids. Three patients died with progressive pulmonary failure and other organ system involvement. Four of 7 DAH patients (57{\%}) survived to discharge, but 3 died from disease relapse at days 116, 138, and 273 post-HCT. Conclusion. DAH occurred more frequently in allogeneic HCT recipients compared with autologous recipients. Onset of DAH coincided closely with white blood cell engraftment. Although associated with significant respiratory failure and need for mechanical ventilation, HCT patients can survive DAH.",
keywords = "Bone marrow transplant, Bronchoalveolar lavage, Pediatric, Pulmonary hemorrhage, Respiratory failure",
author = "Judith Heggen and Carla West and Ellen Olson and Thomas Olson and Gerald Teague and James Fortenberry and Yeager, {Andrew M}",
year = "2002",
doi = "10.1542/peds.109.5.965",
language = "English (US)",
volume = "109",
pages = "965--971",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Diffuse alveolar hemorrhage in pediatric hematopoietic cell transplant patients

AU - Heggen, Judith

AU - West, Carla

AU - Olson, Ellen

AU - Olson, Thomas

AU - Teague, Gerald

AU - Fortenberry, James

AU - Yeager, Andrew M

PY - 2002

Y1 - 2002

N2 - Objective. Diffuse alveolar hemorrhage (DAH) is defined as a syndrome of hypoxia, dyspnea, infiltrates on chest radiograph, and bloody fluid on successive bronchoalveolar lavages without apparent infection. Minimal experience has been reported with DAH after hematopoietic cell transplant (HCT) in children. We reviewed the incidence, management and outcome of DAH in a pediatric HCT population. Methods. Retrospective review of 138 patients undergoing allogeneic (n = 89) or autologous (n = 49) HCT at a referral children's medical center between January 1996 and April 2000. Results. Seven (5.1%) of 138 patients met criteria for DAH; all were allogeneic recipients. Mean age of DAH patients was 11 years (range: 1.4-15.2). Median onset of DAH following HCT was day 24 (range: 10-50), median day of engraftment day 20 and white blood cell count 0.54 × 109/L (range: <0.1-7.03), with no difference between survivors and nonsurvivors. All patients developed clinical respiratory failure and 6 required intubation, with PaO2/fraction of inspired oxygen <200. Patients were intubated a median of 12 days (range: 1-75). All patients experienced >1 episode of bleeding and 3 patients required reintubation after successful extubation resulting from recurrent DAH. Bronchoalveolar lavage fluid cultures were negative for viruses, bacteria and fungi. All DAH patients received steroids. Three patients died with progressive pulmonary failure and other organ system involvement. Four of 7 DAH patients (57%) survived to discharge, but 3 died from disease relapse at days 116, 138, and 273 post-HCT. Conclusion. DAH occurred more frequently in allogeneic HCT recipients compared with autologous recipients. Onset of DAH coincided closely with white blood cell engraftment. Although associated with significant respiratory failure and need for mechanical ventilation, HCT patients can survive DAH.

AB - Objective. Diffuse alveolar hemorrhage (DAH) is defined as a syndrome of hypoxia, dyspnea, infiltrates on chest radiograph, and bloody fluid on successive bronchoalveolar lavages without apparent infection. Minimal experience has been reported with DAH after hematopoietic cell transplant (HCT) in children. We reviewed the incidence, management and outcome of DAH in a pediatric HCT population. Methods. Retrospective review of 138 patients undergoing allogeneic (n = 89) or autologous (n = 49) HCT at a referral children's medical center between January 1996 and April 2000. Results. Seven (5.1%) of 138 patients met criteria for DAH; all were allogeneic recipients. Mean age of DAH patients was 11 years (range: 1.4-15.2). Median onset of DAH following HCT was day 24 (range: 10-50), median day of engraftment day 20 and white blood cell count 0.54 × 109/L (range: <0.1-7.03), with no difference between survivors and nonsurvivors. All patients developed clinical respiratory failure and 6 required intubation, with PaO2/fraction of inspired oxygen <200. Patients were intubated a median of 12 days (range: 1-75). All patients experienced >1 episode of bleeding and 3 patients required reintubation after successful extubation resulting from recurrent DAH. Bronchoalveolar lavage fluid cultures were negative for viruses, bacteria and fungi. All DAH patients received steroids. Three patients died with progressive pulmonary failure and other organ system involvement. Four of 7 DAH patients (57%) survived to discharge, but 3 died from disease relapse at days 116, 138, and 273 post-HCT. Conclusion. DAH occurred more frequently in allogeneic HCT recipients compared with autologous recipients. Onset of DAH coincided closely with white blood cell engraftment. Although associated with significant respiratory failure and need for mechanical ventilation, HCT patients can survive DAH.

KW - Bone marrow transplant

KW - Bronchoalveolar lavage

KW - Pediatric

KW - Pulmonary hemorrhage

KW - Respiratory failure

UR - http://www.scopus.com/inward/record.url?scp=0036247423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036247423&partnerID=8YFLogxK

U2 - 10.1542/peds.109.5.965

DO - 10.1542/peds.109.5.965

M3 - Article

VL - 109

SP - 965

EP - 971

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -